Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1423 studies found for:    Kennedy's Disease
Show Display Options
Rank Status Study
21 Recruiting Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Condition: Triple Negative Breast Cancer
Intervention: Drug: GTx-024
22 Recruiting Study of Hepatic Function in Patients With Spinal and Bulbar Muscular Atrophy
Conditions: Liver;   Motor Neuron Disease
23 Active, not recruiting A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
Condition: Prostate Cancer
Interventions: Drug: Galeterone;   Drug: Enzalutamide
24 Terminated GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Triple Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: cisplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI;   Drug: GDC -0941
25 Recruiting Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients
Condition: Breast Cancer
Intervention: Drug: Bicalutamide
26 Completed Effect of Functional Exercise in Patients With Spinal Bulbar Muscular Atrophy
Condition: Motor Neuron Disease
Interventions: Behavioral: A functional exercise program;   Behavioral: A stretching exercise program
27 Recruiting Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
Condition: Salivary Gland Cancer
Interventions: Drug: bicalutamide + triptorelin;   Drug: Cisplatin + Doxorubicin;   Drug: Carboplatin + Paclitaxel
28 Recruiting Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078
Condition: Cachexia
Interventions: Drug: GSK2881078;   Drug: Placebo;   Drug: Itraconazole
29 Active, not recruiting Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy
Condition: Prostate Cancer
Intervention: Procedure: Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging
30 Terminated
Has Results
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Nilutamide;   Drug: Dasatinib
31 Recruiting Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
Condition: Salivary Cancer
Intervention: Drug: enzalutamide
32 Withdrawn STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling
Condition: Adenocarcinoma of the Prostate
Interventions: Drug: STA9090;   Drug: STA9090 with Dutasteride
33 Active, not recruiting The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: ARN-509;   Drug: LHRH Agonist
34 Recruiting A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF
Condition: Prostate Cancer
Interventions: Biological: pTVG-AR;   Biological: gm-csf
35 Recruiting Phase IIB Neoadjuvant Enzalutamide (ZT) Plus Taxol for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer (AR+ TNBC)
Condition: Breast Cancer
Interventions: Drug: Enzalutamide;   Drug: Paclitaxel
36 Withdrawn Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery
Condition: Breast Cancer Female
Interventions: Drug: oral microencapsulated diindolylmethane;   Other: laboratory biomarker analysis
37 Recruiting A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
Conditions: Advanced Breast Cancer;   Human Epidermal Growth Factor Receptor 2 (HER2);   HER2 Amplified
Interventions: Drug: enzalutamide;   Drug: trastuzumab
38 Active, not recruiting A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
Condition: Prostatic Neoplasms, Castration-Resistant
Intervention: Drug: JNJ-56021927
39 Recruiting Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Bicalutamide;   Drug: Aromatase Inhibitor
40 Recruiting Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer
Conditions: Metastatic Prostate Carcinoma;   Metastatic Prostatic Adenocarcinoma;   Prostate Carcinoma Metastatic to the Bone
Interventions: Procedure: Robotic Assisted Radical Prostatectomy;   Procedure: Conventional open retropubic radical prostectomy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Drug: ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years